Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase <scp>III</scp> trial

20260 citationsJournal Articlehybrid Open Access

Authors

Seung Wook Lee · Yonsei University

Seung Hwan Lee · Yonsei University

J H Kim · Soonchunhyang University

Joon Hwa Noh · Kwangju Christian Hospital

Jun Ho Lee · Eulji University

U Shin Ha · The Catholic University of Korea Seoul St. Mary's Hospital

Cheol Young Oh ·

Abstract

The FDC 0.5/5 mg demonstrated superior efficacy, and an acceptable safety profile compared with dutasteride and tadalafil monotherapies in patients with BPH.

Topics & Keywords

Urinary Bladder and Prostate Research Prostate Cancer Treatment and Research Sexual function and dysfunction studies

Publication Details

Published in: British Journal of Urology

Volume 137, Issue 4, pp. 698-707

DOI: 10.1111/bju.70163

Field-Weighted Citation Impact: 0.00

Command Palette

Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase <scp>III</scp> trial

Authors

Abstract

Topics & Keywords

Publication Details